Barclays has started its coverage of Merck (MRK), drawing attention to the company's promising pipeline catalysts as key drivers for future growth.

Merck is restructuring its business by separating its oncology division from non-cancer drug operations, a move reportedly in preparation for the 2028 patent expiry of its blockbuster cancer treatment, Keytruda.

Deutsche Bank has upgraded Merck (MRK) to a 'Buy' rating, expressing optimism about the company's future beyond the patent expiration of its key drug, Keytruda.

Merck & Co. saw its stock advance, driven by robust sales of its drug Keytruda and favorable results from recent clinical trials.

Pharmaceutical giant Merck is set to establish a distinct cancer unit as the company prepares for an impending patent cliff.

Merck announced plans to divide its human health business into two separate divisions, separating its cancer franchise from non-oncology medicines, to mitigate the impact of Keytruda patent loss.

Analysts are providing their perspectives on the future trajectory of Merck & Co., Inc. (MRK), assessing its potential performance.

The increasing complexity of chips, driven by artificial intelligence, is expected to lead to a significant surge in the semiconductor materials market.

Merck announced positive results from its phase 3 second-season RSV data for the vaccine ENFLONSIA, indicating continued efficacy.